75 related articles for article (PubMed ID: 3842636)
21. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
[TBL] [Abstract][Full Text] [Related]
22. Bilateral swollen eyelids occurring during adjuvant treatment with tamoxifen for early breast cancer.
Jaspers H; Blaisse R; Maessen-Visch B; Mattijssen V
Neth J Med; 2009 Jun; 67(6):245-6. PubMed ID: 19749398
[No Abstract] [Full Text] [Related]
23. [Metrorrhagia and tamoxifen. Apropos of 22 patients treated for cancer of the breast].
Le Bouëdec G; De Latour M; Feillel V; Dauplat J
J Gynecol Obstet Biol Reprod (Paris); 1990; 19(7):889-94. PubMed ID: 2277172
[TBL] [Abstract][Full Text] [Related]
24. Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer.
Jordan VC
Annu Rev Pharmacol Toxicol; 1995; 35():195-211. PubMed ID: 7598491
[TBL] [Abstract][Full Text] [Related]
25. Tamoxifen and breast cancer--from palliation to prevention.
Rich SE
Cancer Nurs; 1993 Oct; 16(5):341-6. PubMed ID: 7505194
[TBL] [Abstract][Full Text] [Related]
26. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
27. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
28. Role of tamoxifen in the long-term treatment and prevention of breast cancer.
Jordan VC
Oncology (Williston Park); 1988 Sep; 2(9):19-28. PubMed ID: 3079292
[TBL] [Abstract][Full Text] [Related]
29. Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - results from a prospective, single center, case control study.
Kovac M; Kovac Z; Tomasevic Z; Vucicevic S; Djordjevic V; Pruner I; Radojkovic D
Eur J Intern Med; 2015 Jan; 26(1):63-7. PubMed ID: 25592075
[TBL] [Abstract][Full Text] [Related]
30. DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group.
Maier S; Nimmrich I; Koenig T; Eppenberger-Castori S; Bohlmann I; Paradiso A; Spyratos F; Thomssen C; Mueller V; Nährig J; Schittulli F; Kates R; Lesche R; Schwope I; Kluth A; Marx A; Martens JW; Foekens JA; Schmitt M; Harbeck N;
Eur J Cancer; 2007 Jul; 43(11):1679-86. PubMed ID: 17601725
[TBL] [Abstract][Full Text] [Related]
31. Cognitive impairment associated with adjuvant therapy in breast cancer.
Bender CM; Sereika SM; Berga SL; Vogel VG; Brufsky AM; Paraska KK; Ryan CM
Psychooncology; 2006 May; 15(5):422-30. PubMed ID: 16097037
[TBL] [Abstract][Full Text] [Related]
32. [Postmenopausal hemorrhage and endometrial cancer in tamoxifen therapy].
Krause A; Gerber B
Zentralbl Gynakol; 1994; 116(1):44-7. PubMed ID: 8147180
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant endocrine therapy for early breast cancer: the story so far.
Gradishar WJ
Cancer Invest; 2010 May; 28(4):433-42. PubMed ID: 20307199
[TBL] [Abstract][Full Text] [Related]
34. [Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].
Tuxen MK; Nielsen DL; Lindberg H; Kamby C
Ugeskr Laeger; 2007 Jan; 169(4):297-9. PubMed ID: 17274922
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial.
Mouridsen H; Keshaviah A; Coates AS; Rabaglio M; Castiglione-Gertsch M; Sun Z; Thürlimann B; Mauriac L; Forbes JF; Paridaens R; Gelber RD; Colleoni M; Smith I; Price KN; Goldhirsch A
J Clin Oncol; 2007 Dec; 25(36):5715-22. PubMed ID: 17998546
[TBL] [Abstract][Full Text] [Related]
36. Malignant mixed mesodermal tumor after tamoxifen therapy for breast cancer.
Hubalek M; Ramoni A; Mueller-Holzner E; Marth C
Gynecol Oncol; 2004 Oct; 95(1):264-6. PubMed ID: 15385144
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant treatment for breast cancer in the elderly.
Marchei P; Bianco V; Pignatelli E; Chiodini S; Santini D; Carico E; Marchei M; Vecchione A
Anticancer Res; 1996; 16(2):911-3. PubMed ID: 8687150
[TBL] [Abstract][Full Text] [Related]
38. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
[TBL] [Abstract][Full Text] [Related]
39. Endometrial cancer in patients with breast carcinoma treated with tamoxifen: report of two cases and the literature overview.
Sliwińska M; Wojtacki J; Sliwiński W
Med Sci Monit; 2000; 6(2):399-406. PubMed ID: 11208346
[TBL] [Abstract][Full Text] [Related]
40. [Morphologic endometrium changes with tamoxifen].
Dallenbach-Hellweg G; Hahn U; Schmidt D
Zentralbl Gynakol; 1996; 118(6):365-9. PubMed ID: 8768015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
